Cover Image
市場調查報告書

化療誘發性貧血:開發中產品分析

Chemotherapy Induced Anemia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192523
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
化療誘發性貧血:開發中產品分析 Chemotherapy Induced Anemia - Pipeline Review, H2 2016
出版日期: 2016年08月17日 內容資訊: 英文 71 Pages
簡介

化療誘發性貧血是治療癌症時最常見的副作用。有嚴重疲勞、虛勞、焦慮症、缺乏體力,呼吸急促,頭痛,血色壞,心搏過速,心跳,胸部疼痛,暈眩,認知功能障礙,性慾衰退,無法執行日常活動,伴隨貧血的憂鬱症等症狀。原因有年齡,併發症、經常性治療等。

本報告提供化療誘發性貧血的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

化療誘發性貧血概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

化療誘發性貧血:企業開發中的治療藥

化療誘發性貧血:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

化療誘發性貧血:企業開發中的產品

化療誘發性貧血的治療藥的開發企業

  • 3SBio Inc.
  • BIOCAD
  • Chong Kun Dang Pharmaceutical Corp.
  • Dr. Reddy's Laboratories Limited
  • Galenica Ltd.
  • Panacea Biotec Limited
  • Pfizer Inc.
  • PharmaEssentia Corporation
  • PhytoHealth Corporation
  • Pieris Pharmaceuticals Inc
  • Sandoz International GmbH
  • SBI Pharmaceuticals Co., Ltd.
  • Therapure Biopharma Inc.
  • Tolero Pharmaceuticals, Inc.

化療誘發性貧血:治療藥的評估

  • 單劑產品
  • 並用治療藥
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

化療誘發性貧血:暫停中的計劃

化療誘發性貧血:開發中止的產品

化療誘發性貧血:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8368IDB

Summary

Global Markets Direct's, 'Chemotherapy Induced Anemia - Pipeline Review, H2 2016', provides an overview of the Chemotherapy Induced Anemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia
  • The report reviews pipeline therapeutics for Chemotherapy Induced Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Chemotherapy Induced Anemia therapeutics and enlists all their major and minor projects
  • The report assesses Chemotherapy Induced Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Anemia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chemotherapy Induced Anemia Overview
  • Therapeutics Development
    • Pipeline Products for Chemotherapy Induced Anemia - Overview
  • Chemotherapy Induced Anemia - Therapeutics under Development by Companies
  • Chemotherapy Induced Anemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Chemotherapy Induced Anemia - Products under Development by Companies
  • Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development
    • 3SBio Inc.
    • BIOCAD
    • Chong Kun Dang Pharmaceutical Corp.
    • Dr. Reddy's Laboratories Limited
    • Galenica Ltd.
    • Panacea Biotec Limited
    • Pfizer Inc.
    • PharmaEssentia Corporation
    • PhytoHealth Corporation
    • Pieris Pharmaceuticals Inc
    • Sandoz International GmbH
    • SBI Pharmaceuticals Co., Ltd.
    • Therapure Biopharma Inc.
    • Tolero Pharmaceuticals, Inc.
  • Chemotherapy Induced Anemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epoetin zeta - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ferric carboxymaltose - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-1116 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PHN-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRS-080 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SSS-06 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TBI-304H - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-0184 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-0413 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TXA-302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chemotherapy Induced Anemia - Dormant Projects
  • Chemotherapy Induced Anemia - Discontinued Products
  • Chemotherapy Induced Anemia - Product Development Milestones
    • Featured News & Press Releases
      • Mar 11, 2015: Therapure Innovations Receives FDA Approval to Proceed with a Phase 1 Clinical Trial of Its Novel Anemia Therapeutic TBI 304H
      • Oct 30, 2012: SBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia
      • Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health
      • Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology
      • Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting
      • Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology
      • Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended
      • Aug 09, 2010: Dr Reddy's Launches Darbepoetin Alfa For Treatment Of Anemia In India
      • Dec 01, 2008: International presentation of clinical safety and efficacy data for Binocrit, the world's first complex biosimilar
      • Jan 07, 2008: Sandoz and Gambro form strategic alliance
      • Aug 31, 2007: European Commission approves Sandoz's epoetin alfa Binocrit
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chemotherapy Induced Anemia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Chemotherapy Induced Anemia - Pipeline by 3SBio Inc., H2 2016
  • Chemotherapy Induced Anemia - Pipeline by BIOCAD, H2 2016
  • Chemotherapy Induced Anemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016
  • Chemotherapy Induced Anemia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016
  • Chemotherapy Induced Anemia - Pipeline by Galenica Ltd., H2 2016
  • Chemotherapy Induced Anemia - Pipeline by Panacea Biotec Limited, H2 2016
  • Chemotherapy Induced Anemia - Pipeline by Pfizer Inc., H2 2016
  • Chemotherapy Induced Anemia - Pipeline by PharmaEssentia Corporation, H2 2016
  • Chemotherapy Induced Anemia - Pipeline by PhytoHealth Corporation, H2 2016
  • Chemotherapy Induced Anemia - Pipeline by Pieris Pharmaceuticals Inc, H2 2016
  • Chemotherapy Induced Anemia - Pipeline by Sandoz International GmbH, H2 2016
  • Chemotherapy Induced Anemia - Pipeline by SBI Pharmaceuticals Co., Ltd., H2 2016
  • Chemotherapy Induced Anemia - Pipeline by Therapure Biopharma Inc., H2 2016
  • Chemotherapy Induced Anemia - Pipeline by Tolero Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Chemotherapy Induced Anemia - Dormant Projects, H2 2016
  • Chemotherapy Induced Anemia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Chemotherapy Induced Anemia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top